SELP and lymphoma: These results agree with previous observations of P-selectin overexpression in tumor-associated endothelium in glioblastoma, lung, ovarian, lymphoma, breast, and other cancer subtypes20,21, which suggests that PSGL-1 could be used to target the tumor-associated endothelium in other cancer subtypes.